MRI评估西罗莫司治疗的儿童广泛淋巴管畸形的疗效
回顾性分析25例接受西罗莫司治疗的广泛淋巴管畸形患儿,比较基线与随访MRI的病灶体积指数和T2信号比。随访间隔平均22.1±13.8个月,体积指数从728±970降至345±501 mL/m2(p<.001),信号比从0.81±0.29降至0.59±0.26(p<.001),92%患儿体积下降超过10%。
要点
- 西罗莫司治疗后MRI显示病灶体积和T2信号显著降低,可用于疗效评估。
- 92%患儿体积下降超过10%,平均体积变化-46.4%±28.2%。
- 年龄<2岁和颅颈部病灶的体积下降更明显(p=.008和p=.03)。
核心结论
- 西罗莫司治疗儿童广泛淋巴管畸形与MRI上病灶体积和T2信号显著降低相关,且年龄较小和颅颈部病灶的体积下降更明显。
研究设计与样本
- 回顾性研究,纳入25例接受西罗莫司治疗的广泛淋巴管畸形患儿,由两名儿科放射科医师独立测量基线和随访MRI的病灶体积指数和信号比。
关键影像表现/征象
- 随访T2WI上病灶信号比降低,平均信号比变化-23.8%±22.7%(p<.001);体积变化与信号变化中度相关(r=0.469;p=.02)。
诊断标准与关键数值
- 体积指数以患者体表面积(m2)标准化,信号比以脑脊液信号标准化;体积下降超过10%定义为有效。
临床应用与阅片要点
- MRI可用于评估西罗莫司治疗淋巴管畸形的疗效,体积和信号变化是潜在指标;阅片时需注意年龄和病灶部位对体积变化的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Extensive lymphatic malformations (LMs) may cause substantial morbidity. The mammalian target of rapamycin (mTOR) inhibitor sirolimus shows promise for treating vascular anomalies, although response assessment is not standardized. OBJECTIVE. The purpose of this study was to retrospectively characterize changes seen on MRI of children with extensive LMs treated with sirolimus. METHODS. Twenty-five children treated with sirolimus for extensive LMs were included. Baseline MRI was defined as the MRI examination performed closest to therapy initiation; follow-up MRI was defined as the most recent MRI examination performed while the patient was receiving therapy. Two pediatric radiologists independently determined MRI lesion volume by tracing lesion contours on all slices (normalized to patient body surface area expressed in square meters) and determined signal by placing an ROI on the dominant portion of the lesions (normalized to CSF signal) on baseline and follow-up T2-weighted MRI sequences. Interreader agreement was determined, and values were averaged for further analysis. Volume and signal changes were compared with patient, lesion, and treatment characteristics. RESULTS. The mean (± SD) interval between initiation of sirolimus treatment and follow-up MRI was 22.1 ± 13.8 months. The mean lesion volume index on baseline and follow-up MRI was 728 ± 970 and 345 ± 501 mL/m2, respectively (p < .001). Ninety-two percent of children showed a decrease in lesion volume index that was greater than 10% (mean volume change, -46.4% ± 28.2%). Volume change was inversely correlated with age (r = -0.466; p = .02). The mean volume change was -64.7% ± 25.4% in children younger than 2 years old versus -32.0% ± 21.6% in children 2 years old or older (p = .008). The mean volume change was -58.1% ± 24.0% for craniocervical lesions versus -35.5% ± 28.2% for lesions involving the trunk and/or extremities (p = .03). Mean lesion signal ratio on baseline and follow-up MRI was 0.81 ± 0.29 and 0.59 ± 0.26, respectively (p < .001). Mean signal ratio change was -23.8% ± 22.7%. Volume and signal changes were moderately correlated (r = 0.469; p = .02). Volume and signal changes were not associated with sex, lesion subtype, serum concentration of sirolimus, or the interval between sirolimus initiation and follow-up MRI (p > .05). Interreader agreement for volume index change was excellent (intraclass correlation coefficient, 0.983), and that for signal ratio change was moderate to good (intraclass correlation coefficient, 0.764). CONCLUSION. Sirolimus treatment of extensive LMs in children is associated with significant reductions in volume and signal on T2-weighted MRI. The decrease in volume is greater in younger children and craniocervical lesions. CLINICAL IMPACT. The results may facilitate development of standardized MRI-based criteria for assessing the response of vascular malformations to pharmacotherapy.
引用
- Durand R, Reid JR, Belasco JB, et al. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus. AJR Am J Roentgenol. 2021. PMID: 33405944. doi:10.2214/AJR.20.24378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。